The Worldwide Retinal Biologics Market is Projected to reach USD 20.7 Billion by 2030, at a CAGR of 5.4%
Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Retinal Biologics Market Growth, Trends and Report Highlights
According to a new report, published by KBV research, The Global Retinal Biologics Market size is expected to reach $20.7 billion by 2030, rising at a market growth of 5.4% CAGR during the forecast period.
The Diabetic Retinopathy segment would register a CAGR of 5.7% during (2023 - 2030). The rising population of diabetics is one of the major contributors to the occurrence of diabetic retinopathy or DR. The International Diabetes Federation (IDF) estimates that 643 million persons will have diabetes by 2030. It might therefore increase the chance of DR, which is one of the most common causes of vision loss in persons with diabetes.
The VEGF-A Antagonist is leading the Global Retinal Biologics Market by Drug Class in 2022; thereby, achieving a market value of $16.1 billion by 2030. In order to cure eye injury and improve corneal wound healing, VEGF-A antagonists are utilized. The increased incidence of other retinal diseases like uveitis and orbital inflammation is also anticipated to have a positive impact on the market for retinal biologics. Diabetes-related macular edema and retinopathy are frequently treated with VEGF-A antagonists.
The Hospital Pharmacy segment is showcasing a CAGR of 5% during the forecast period. The segment is expanding as a result of hospital pharmacists' accessibility to a variety of specialist drugs, including retinal biologics. Furthermore, these drugs are frequently prescribed and given in a hospital setting, ensuring that patients get the appropriate care for their retinal illnesses. Hospitals provide a wide range of services to their numerous and diverse patient populations.
The North America region dominated the Global Retinal Biologics Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $10.9 billion by 2030. The Europe market is poised to grow at a CAGR of 5.7% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 6.3% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/retinal-biologics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Novartis AG, Amgen, Inc., AbbVie, Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., MeiraGTx Holdings plc and Oxurion NV.
Global Retinal Biologics Market Segmentation
By Indication
- Macular Degeneration
- Diabetic Retinopathy
- Others
By Drug Class
- VEGF-A Antagonist
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Novartis AG
- Amgen, Inc.
- AbbVie, Inc.
- Bayer AG
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- Bausch Health Companies, Inc.
- F.Hoffmann-La Roche Ltd.
- MeiraGTx Holdings plc
- Oxurion NV
Related Reports:
North America Retinal Biologics Market Size, Share to 2030
- July-2023
- 111 Pages
LAMEA Retinal Biologics Market Size, Projection, 2023-2030
- July-2023
- 119 Pages
Europe Retinal Biologics Market Size & Share by 2023-2030
- July-2023
- 119 Pages
Asia Pacific Retinal Biologics Market Size & Share, 2030
- July-2023
- 119 Pages